BACKGROUND:Combination therapy is an effective method to reduce the blood pressure (BP) for patients with hypertension. This study was performed to evaluate the efficacy and safety of benazepril/lercanidipine compared with benazepril alone in patients with mild-to-moderate hypertension.
METHODS:One hundred and eighty-one patients with mild-to-moderate primary hypertension were assigned in this randomized, single-blind, parallel-group study and were randomly divided into group A (benazepril 10 mg/lercanidipine 10 mg) and group B (benazepril 10 mg) for 8 weeks. At 4 weeks, the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥ 90 mmHg. BP control and side effects were evaluated at the end of 1, 4 and 8 weeks.
RESULTS:The baseline characteristics of the two groups were similar. The BP in both groups decreased from the baseline (P < 0.05). At the end of 4 and 8 weeks, Benazepril/Lercanidipine produced greater BP reduction than Benazepril alone (P < 0.05). The comparison of the rate of BP control for the benazepril/lercanidipine and benazepril groups at the end of 1, 4, and 8 weeks were 41.2% vs. 37.6% (P > 0.05), 67.1% vs. 44.7% (P < 0.05), and 71.8% vs. 45.9% (P < 0.05). There was no significant difference of side effects between the two groups.
CONCLUSION:The benazepril/lercanidipine combination is more effective in reducing BP than benazepril alone, while it does not increase the incidence of side effects.
-
【Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension.].
【疗效和安全性：轻度至中度高血压患者中贝那普利/雷卡地平与贝那普利的组合治疗。】
复制标题
收藏
DOI：文章类型：杂志文章
复制DOI
译文
背景：联合治疗是降低高血压患者血压的有效方法。本研究旨在评估贝那普利/雷卡地平与轻度至中度高血压患者相比单独使用贝那普利的疗效和安全性。
方法：118例轻度至中度原发性高血压患者被纳入这项随机，单盲，平行组研究，并随机分为A组（苯那普利10 mg / lercanidipine 10 mg）和B组（苯那普利10毫克）持续8周。如果舒张压（DBP）保持≥90 mmHg，则在4周时将贝那普利的剂量最高滴定至20 mg。在第1、4和8周结束时评估血压控制和副作用。
结果：两组的基线特征相似。两组的血压均较基线下降（P <0.05）。在第4和第8周结束时，贝那普利/来那地平产生的BP降低量大于单独的贝那普利（P <0.05）。在第1、4和8周结束时，贝那普利/雷卡地平和贝那普利组的BP控制率比较分别为41.2％vs. 37.6％（P> 0.05），67.1％vs. 44.7％（P <0.05 ），分别为71.8％和45.9％（P <0.05）。两组之间的副作用没有显着差异。
结论：贝那普利/雷卡地平联合用药比单独使用贝那普利更能有效降低血压，但不会增加副作用的发生率。
方法：118例轻度至中度原发性高血压患者被纳入这项随机，单盲，平行组研究，并随机分为A组（苯那普利10 mg / lercanidipine 10 mg）和B组（苯那普利10毫克）持续8周。如果舒张压（DBP）保持≥90 mmHg，则在4周时将贝那普利的剂量最高滴定至20 mg。在第1、4和8周结束时评估血压控制和副作用。
结果：两组的基线特征相似。两组的血压均较基线下降（P <0.05）。在第4和第8周结束时，贝那普利/来那地平产生的BP降低量大于单独的贝那普利（P <0.05）。在第1、4和8周结束时，贝那普利/雷卡地平和贝那普利组的BP控制率比较分别为41.2％vs. 37.6％（P> 0.05），67.1％vs. 44.7％（P <0.05 ），分别为71.8％和45.9％（P <0.05）。两组之间的副作用没有显着差异。
结论：贝那普利/雷卡地平联合用药比单独使用贝那普利更能有效降低血压，但不会增加副作用的发生率。
